We are live on
!
Find out more
PMEF
Point72 Middle East FZE Portfolio holdings
AUM
$3.38B
1-Year Est. Return
14.09%
This Fund
S&P 500
This Quarter
Est. Return
+3.95%
1 Year Est. Return
+14.09%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.93B
AUM Growth
+$650M
(+28%)
Cap. Flow
+$595M
Cap. Flow
% of AUM
20.29%
Top 10 Holdings %
Top 10 Hldgs %
12.64%
Holding
2,402
New
555
Increased
562
Reduced
449
Closed
831
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$118M |
| 2 |
Cigna
CI
|
+$29.5M |
| 3 |
Lowe's Companies
LOW
|
+$25.4M |
| 4 |
NVIDIA
NVDA
|
+$24.8M |
| 5 |
Visa
V
|
+$23.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Advanced Micro Devices
AMD
|
+$19.2M |
| 2 |
American International
AIG
|
+$14.2M |
| 3 |
Merck
MRK
|
+$13.6M |
| 4 |
Booking.com
BKNG
|
+$13M |
| 5 |
Zoetis
ZTS
|
+$12M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 11% |
| 2 | Healthcare | 8.44% |
| 3 | Consumer Discretionary | 8.14% |
| 4 | Financials | 7.12% |
| 5 | Industrials | 6.24% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ICVX
1476
DELISTED
Icosavax, Inc. Common Stock
ICVX
| $11.6K | ﹤0.01% |
+2,002
| New | +$17.3K |
|
1477
Lantronix
LTRX
$272M
| $11.4K | ﹤0.01% |
+2,619
| New | +$12.3K |
|
1478
ProQR Therapeutics
PRQR
$261M
| $11.2K | ﹤0.01% |
+5,252
| New | +$16.1K |
|
|
INZY
1479
DELISTED
Inozyme Pharma
INZY
| $10.9K | ﹤0.01% |
+1,897
| New | +$5.01K |
|
1480
Douglas Elliman
DOUG
$183M
| $10.6K | ﹤0.01% |
+3,571
| New | +$14.2K |
|
1481
Peapack-Gladstone Financial
PGC
$822M
| $10.4K | ﹤0.01% |
350
+54
| +18% | +$1.91K |
|
1482
CorMedix
CRMD
$639M
| $10.3K | ﹤0.01% |
+2,477
| New | +$10.1K |
|
1483
Alphatec Holdings
ATEC
$1.51B
| $10.2K | ﹤0.01% |
656
-5,599
| -90% | -$79.2K |
|
1484
Coherus Oncology
CHRS
$176M
| $9.96K | ﹤0.01% |
+1,456
| New | +$11.3K |
|
1485
Pyxis Oncology
PYXS
$191M
| $9.81K | ﹤0.01% |
+2,447
| New | +$4.89K |
|
1486
Ameriprise Financial
AMP
$50.4B
| $9.81K | ﹤0.01% |
32
-392
| -92% | -$128K |
|
1487
Prelude Therapeutics
PRLD
$428M
| $9.58K | ﹤0.01% |
+1,680
| New | +$10.2K |
|
|
GTHX
1488
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
| $9.3K | ﹤0.01% |
+3,471
| New | +$16.7K |
|
1489
Sight Sciences
SGHT
$458M
| $9.27K | ﹤0.01% |
+1,061
| New | +$11.8K |
|
|
UDMY
1490
DELISTED
Udemy
UDMY
| $9.02K | ﹤0.01% |
1,021
-6,656
| -87% | -$70.2K |
|
1491
LanzaTech
LNZA
$68.9M
| $8.93K | ﹤0.01% |
+23
| New | +$15.4K |
|
1492
Advantage Solutions
ADV
$423M
| $8.89K | ﹤0.01% |
+225
| New | +$12.7K |
|
1493
Microvast
MVST
$341M
| $8.83K | ﹤0.01% |
+7,122
| New | +$10.3K |
|
1494
Eversource Energy
ES
$27.2B
| $8.77K | ﹤0.01% |
+112
| New | +$8.85K |
|
1495
Mid-America Apartment Communities
MAA
$15.6B
| $8.68K | ﹤0.01% |
+57
| New | +$9.04K |
|
1496
PDF Solutions
PDFS
$2.13B
| $8.39K | ﹤0.01% |
198
-1,261
| -86% | -$44.2K |
|
|
VRAY
1497
DELISTED
ViewRay, Inc.
VRAY
| $7.97K | ﹤0.01% |
2,304
-2,443
| -51% | -$10.3K |
|
1498
Vital Farms
VITL
$498M
| $7.54K | ﹤0.01% |
+493
| New | +$7.81K |
|
|
NVTA
1499
DELISTED
Invitae Corporation
NVTA
| $7.53K | ﹤0.01% |
5,578
-23,083
| -81% | -$45.5K |
|
1500
American Superconductor
AMSC
$1.53B
| $7.38K | ﹤0.01% |
+1,503
| New | +$7.55K |
|
Similar funds
CC
SS
GW
WMSA
GC
WP
BWM
DI
Point72 Middle East FZE's Q1 2023 Portfolio in Review
As of Q1 2023, Point72 Middle East FZE held 2,402 positions worth $2.93B, up 28% from $2.28B the previous quarter. Its ten largest holdings account for 13% of the portfolio.
Point72 Middle East FZE deployed $595M of net new capital in Q1 2023, opening 555 new positions and adding to 562 existing holdings. Its largest new stake was State Street SPDR S&P 500 ETF Trust: 295,544 shares worth $121M.
By sector, the portfolio is most concentrated in Technology at 11% of assets, up from 10% a quarter earlier, followed by Healthcare and Consumer Discretionary.
On the sell side, the largest reduction was Merck, an estimated $13.6M trimmed.
- Point72 Middle East FZE's largest Q1 2023 buy was State Street SPDR S&P 500 ETF Trust: 295,544 shares worth $121M.
- Point72 Middle East FZE added most to NVIDIA in Q1 2023, an estimated $24.8M increase.
- Point72 Middle East FZE's biggest Q1 2023 reduction was Merck, cutting an estimated $13.6M.
- Point72 Middle East FZE fully exited Advanced Micro Devices in Q1 2023, selling an estimated $19.2M.
- Point72 Middle East FZE's ten largest holdings make up 13% of its $2.93B portfolio in Q1 2023.
- Point72 Middle East FZE opened 555 new positions and closed 831 in Q1 2023.
- Point72 Middle East FZE's portfolio value rose 28% quarter-over-quarter to $2.93B.
Based on Point72 Middle East FZE's 13F filing for Q1 2023, filed 15 May 2023.